Results 141 to 150 of about 35,270 (248)

Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 6, June 2026.
ABSTRACT Background Intravenous push (IVP) administration of cefepime increases ease of preparation and limits the need for small volume parenterals. The data on IVP pharmacokinetic/pharmacodynamic (PK/PD) parameters are limited, but may be especially relevant in critically ill patients with altered PK/PD for time‐dependent antibiotics like cefepime ...
Susan E. Smith, Rehana Bagodiya, Phuong Luong, Sakshi Shinde, Christopher M. Bland, Christopher Barry, Michael G. Bartlett, Nicholas R. Fox, Trisha N. Branan   +8 more
wiley   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Home‐Based Versus In‐Hospital Care in Pediatrics: A Systematic Review of Cost‐Effectiveness Studies

World Medical &Health Policy, Volume 18, Issue 2, June 2026.
ABSTRACT Home‐based care has emerged as a potential alternative to traditional hospital‐based care for children and adolescents worldwide. This systematic review aimed to systematically gather and critically assess the available evidence on the cost‐effectiveness of home‐based versus in‐hospital care for pediatric populations globally.
Luís Carlos Lopes‐Júnior, Raphael Manhães Pessanha, Wesley Rocha Grippa, Jonathan Grassi, Luiz Cláudio Barreto Silva Neto, Mariana Rabello Laignier, María Liliana Vásquez Ponce, Karla Anacleto de Vasconcelos, Regina Aparecida Garcia de Lima   +8 more
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, Volume 208, Issue 6, Page 2069-2078, June 2026.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

NEUTROPENIA FEBRIL

, 2021
DAYANE KETLYN DA CUNHA SANTOS, JOSÉ FONTES JÚNIOR, JOSÉ CLEYTON DE OLIVEIRA SANTOS   +2 more
openaire   +1 more source

Use of Scores in Risk Stratification of Febrile Neutropenia-A Scoping Review. [PDF]

Cancers (Basel)
Fuglkjær AD, Christensen F, Kılıç DK, Poulsen LØ, Jensen P, Niemann CU, El-Galaly TC, Nielsen IE.   +7 more
europepmc   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, Volume 117, Issue 6, Page 1690-1700, June 2026.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Frontline Febrile Neutropenia Antibiotic Treatment Across Institution Types: A Multicenter Survey Study. [PDF]

Open Forum Infect Dis
Castillo M, Gross D, Harding SJ.
europepmc   +1 more source

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, Volume 116, Issue 6, Page 873-882, June 2026.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source